[PDF][PDF] Phase II trial of gefitinib in recurrent glioblastoma

JN Rich, DA Reardon, T Peery, JM Dowell… - Journal of Clinical …, 2004 - academia.edu
JN Rich, DA Reardon, T Peery, JM Dowell, JA Quinn, KL Penne, CJ Wikstrand, LB Van Duyn…
Journal of Clinical Oncology, 2004academia.edu
Phase II Trial of Gefitinib in Recurrent Glioblastoma Page 1 Phase II Trial of Gefitinib in
Recurrent Glioblastoma Jeremy N. Rich, David A. Reardon, Terry Peery, Jeannette M. Dowell,
Jennifer A. Quinn, Kara L. Penne, Carol J. Wikstrand, Lauren B. Van Duyn, Janet E. Dancey,
Roger E. McLendon, James C. Kao, Timothy T. Stenzel, BK Ahmed Rasheed, Sandra E.
Tourt-Uhlig, James E. Herndon II, James J. Vredenburgh, John H. Sampson, Allan H. Friedman,
Darell D. Bigner, and Henry S. Friedman A B S T R A C T Purpose To evaluate the efficacy and …
Purpose
To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
academia.edu